OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angiod Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Abstract

Purpose: : To evaluate the 3–month efficacy of a single dose of IV bevacizumab on the progression SNPDR and PDR by evaluation of ischemic areas and regression of retinal and iris neovascularization

Methods: : 48 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (1.25mg). We evaluated visual acuity (VA) leakage capillary closure ischemic areas (CCIA) and macular edema by clinical and fluorescein angiography. A clinical examination was performed at day 0, 1, 30 and 90. Active leakage was measured by fluorescein angiography at 30 and 90 days.

Results: : 48 patients (32 women, 16 men). 18 SNPDR, 30 PDR. Mean initial visual acuity improved from 20/80 to 20/40 at 3 month evaluation (Friedman Test p= 0.030). CCIA en quadrants improved from 3.33±1.01 to 1.87±0.915 at month 3 (WIlcoxon p=0.003) and macular edema improved from 5.05±3.48 DA to 2.93±2.37 (Wilcoxon p= 0.005). Systemic effects, inflammatory reaction in anterior chamber, endophthalmitis and intraocular hypertension were not observed

Conclusions: : These results indicates the trend that intravitreal bevacizumab decrease ischemic areas, iris and retinal neovascularization in a three months follow–up. Intravitreal bevacizumab reduce progression of PDR in a 3 month period. Improve in visual acuity may be explained by reduction of macular edema. The results suggests that bevacizumab is a potent antiangiogenic that may reduce the progression of SNPDR and PDR.

Keywords: retinal neovascularization • retinal culture • retina